JP2015514090A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514090A5 JP2015514090A5 JP2015503464A JP2015503464A JP2015514090A5 JP 2015514090 A5 JP2015514090 A5 JP 2015514090A5 JP 2015503464 A JP2015503464 A JP 2015503464A JP 2015503464 A JP2015503464 A JP 2015503464A JP 2015514090 A5 JP2015514090 A5 JP 2015514090A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- seq
- amino acid
- antibody
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 29
- 238000009472 formulation Methods 0.000 claims 27
- 102000004965 antibodies Human genes 0.000 claims 19
- 108090001123 antibodies Proteins 0.000 claims 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims 18
- 239000011230 binding agent Substances 0.000 claims 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 5
- 229920001213 Polysorbate 20 Polymers 0.000 claims 5
- 229940068977 Polysorbate 20 Drugs 0.000 claims 5
- 239000007979 citrate buffer Substances 0.000 claims 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 5
- 102100016908 ACKR1 Human genes 0.000 claims 4
- 101710025651 CXCR5 Proteins 0.000 claims 4
- 102100002072 CXCR5 Human genes 0.000 claims 4
- 101710008404 GAPDH Proteins 0.000 claims 4
- 230000001939 inductive effect Effects 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 3
- 102000012220 Member 14 Tumor Necrosis Factor Receptors Human genes 0.000 claims 3
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 3
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims 3
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 3
- 239000005720 sucrose Substances 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 2
- 239000002953 phosphate buffered saline Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 241001529453 unidentified herpesvirus Species 0.000 claims 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 229940090047 Auto-Injector Drugs 0.000 claims 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- 210000004698 Lymphocytes Anatomy 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 230000002378 acidificating Effects 0.000 claims 1
- 239000003708 ampul Substances 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 239000006227 byproduct Substances 0.000 claims 1
- 239000007857 degradation product Substances 0.000 claims 1
- 239000008176 lyophilized powder Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 230000001264 neutralization Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261615539P | 2012-03-26 | 2012-03-26 | |
US61/615,539 | 2012-03-26 | ||
FR1351013 | 2013-02-06 | ||
FR1351013 | 2013-02-06 | ||
PCT/US2013/033881 WO2013148686A2 (en) | 2012-03-26 | 2013-03-26 | Stable igg4 binding agent formulations |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017205914A Division JP6820823B2 (ja) | 2012-03-26 | 2017-10-25 | 安定なIgG4に基づく結合剤の製剤 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015514090A JP2015514090A (ja) | 2015-05-18 |
JP2015514090A5 true JP2015514090A5 (hr) | 2016-03-17 |
JP6265970B2 JP6265970B2 (ja) | 2018-01-24 |
Family
ID=49261390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015503464A Active JP6265970B2 (ja) | 2012-03-26 | 2013-03-26 | 安定なIgG4に基づく結合剤の製剤 |
Country Status (7)
Country | Link |
---|---|
EP (2) | EP3431104A1 (hr) |
JP (1) | JP6265970B2 (hr) |
BR (2) | BR112014023952B1 (hr) |
CA (3) | CA2868401C (hr) |
PL (1) | PL2830658T3 (hr) |
RU (1) | RU2644214C2 (hr) |
WO (1) | WO2013148686A2 (hr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7126454B2 (ja) | 2016-05-12 | 2022-08-26 | ユーシービー バイオファルマ エスアールエル | 医薬組成物 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107446044B (zh) * | 2016-05-30 | 2021-04-30 | 越海百奥药业(绍兴)有限公司 | 一种纯化抗体的方法及所用缓冲液 |
CA3029642A1 (en) | 2016-07-05 | 2018-01-11 | Sanofi | Antibody formulations |
TWI760345B (zh) * | 2016-07-05 | 2022-04-11 | 法商賽諾菲公司 | 抗體調配物 |
US20190359930A1 (en) * | 2016-11-11 | 2019-11-28 | Bayer Aktiengesellschaft | Method for sampling fluid streams for monitoring contaminants in a continuous flow |
AU2017361539B2 (en) * | 2016-11-21 | 2023-06-29 | Eiger Biopharmaceuticals, Inc. | Buffered formulations of exendin (9-39) |
GB201701194D0 (en) | 2017-01-24 | 2017-03-08 | Capella Bioscience Ltd | Antigen binding molecules that bind light |
TWI761453B (zh) | 2017-03-01 | 2022-04-21 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
JP2020509025A (ja) * | 2017-03-01 | 2020-03-26 | メドイミューン・リミテッドMedImmune Limited | モノクローナル抗体製剤 |
GB201708655D0 (en) | 2017-05-31 | 2017-07-12 | Ucb Biopharma Sprl | Cell culture methods |
US11312781B2 (en) | 2018-01-24 | 2022-04-26 | Capella Bioscience Ltd. | Antigen binding molecules that bind LIGHT |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2966592B2 (ja) * | 1991-07-20 | 1999-10-25 | 萩原 義秀 | 安定化されたヒトモノクローナル抗体製剤 |
US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
EP1475101B1 (en) * | 2002-02-14 | 2010-10-27 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing solution pharmaceuticals |
SI3417875T1 (sl) * | 2003-02-10 | 2021-01-29 | Biogen Ma Inc. | Formulacija imunoglobulina in metode za njegovo pripravo |
EP1532983A1 (en) * | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
TW200621282A (en) * | 2004-08-13 | 2006-07-01 | Wyeth Corp | Stabilizing formulations |
WO2006042333A2 (en) | 2004-10-12 | 2006-04-20 | Xencor, Inc. | Prediction and assessment of immunogenicity |
JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
WO2007074880A1 (ja) * | 2005-12-28 | 2007-07-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体含有安定化製剤 |
KR101317235B1 (ko) * | 2006-04-21 | 2013-10-15 | 조마 테크놀로지 리미티드 | 길항제 항-cd40 항체 제약 조성물 |
EA021255B1 (ru) | 2006-08-28 | 2015-05-29 | Киова Хакко Кирин Ко., Лимитед | Антагонистические моноклональные антитела человека, специфичные в отношении light человека |
PE20081477A1 (es) * | 2006-12-11 | 2008-10-18 | Hoffmann La Roche | Formulacion liofilizada mab abeta |
US20090208492A1 (en) * | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
NZ583605A (en) | 2007-08-29 | 2012-10-26 | Sanofi Aventis | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses |
CA2831572C (en) * | 2011-05-02 | 2019-11-26 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
-
2013
- 2013-03-26 RU RU2014142990A patent/RU2644214C2/ru not_active IP Right Cessation
- 2013-03-26 CA CA2868401A patent/CA2868401C/en active Active
- 2013-03-26 EP EP18190556.3A patent/EP3431104A1/en active Pending
- 2013-03-26 CA CA3204402A patent/CA3204402A1/en active Pending
- 2013-03-26 JP JP2015503464A patent/JP6265970B2/ja active Active
- 2013-03-26 WO PCT/US2013/033881 patent/WO2013148686A2/en active Application Filing
- 2013-03-26 BR BR112014023952-5A patent/BR112014023952B1/pt active IP Right Grant
- 2013-03-26 CA CA3123252A patent/CA3123252C/en active Active
- 2013-03-26 EP EP13714505.8A patent/EP2830658B1/en active Active
- 2013-03-26 PL PL13714505T patent/PL2830658T3/pl unknown
- 2013-03-26 BR BR122019026701-4A patent/BR122019026701B1/pt active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7126454B2 (ja) | 2016-05-12 | 2022-08-26 | ユーシービー バイオファルマ エスアールエル | 医薬組成物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015514090A5 (hr) | ||
RU2014142990A (ru) | Стабильные препараты связывающего средства на основе igg4 | |
ES2959257T3 (es) | Composición farmacéutica que comprende construcciones de anticuerpo biespecífico | |
AU2017287743C1 (en) | Stable liquid pharmaceutical preparation | |
HRP20231282T1 (hr) | Stabilna formulacija antitijela | |
JP2024012308A (ja) | 抗lag-3抗体の投薬量レジメンおよびその使用 | |
CN110546160A (zh) | 靶向嵌合蛋白及其用途 | |
CN110573172A (zh) | 靶向的工程化干扰素及其用途 | |
ES2783448T3 (es) | Métodos de tratamiento del lupus eritematoso sistémico utilizando un anticuerpo de dominio dirigido contra CD28 | |
JP2013543505A5 (hr) | ||
JP2016537340A5 (hr) | ||
JP2017536414A5 (hr) | ||
JP2015521593A5 (hr) | ||
ES2769123T3 (es) | Anticuerpos de quimiocinas PAN ELR+ CXC | |
JP2016535020A5 (hr) | ||
RU2016119755A (ru) | Стабильные водные составы на основе антител | |
JP2014503482A5 (hr) | ||
KR20130118879A (ko) | 항―인터류킨―4 수용체(il-4r) 항체를 함유하는 안정화된 제형 | |
CN106659785B (zh) | 包含gm-csf中和化合物的液体制剂 | |
SI2658575T1 (en) | A pharmaceutical formulation comprising a biopharmaceutical | |
RU2019102943A (ru) | Составы на основе антитела | |
TWI639440B (zh) | 包括gm-csf中和化合物之液態配方 | |
CN102791293A (zh) | 肝靶向分子 | |
US11141479B2 (en) | Stable anti-OSMR antibody formulation | |
KR20220011727A (ko) | 항-angptl3 항체를 포함하는 안정화된 제형 |